Milestone Scientific Provides Business Update for the First Quarter of 2018
LIVINSTON, N.J., May 15, 2018 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a dental and medical company that develops and commercializes a growing portfolio of proprietary injection technologies, today provided a business update and announced financial results for the first quarter ended March 31, 2018.
Leonard Osser, Interim Chief Executive Officer of Milestone Scientific, commented, “We have begun to ramp up our commercial efforts around the CompuFlo® Epidural system. We recently hired two experienced sales and marketing executives to spearhead these commercial efforts. Milestone Scientific is now commencing the next phase of our strategy, which involves building out our distribution channels. We have decided to pursue a decentralized sales strategy employing regional distributors with strong physician relationships within their respective territories and clinical specialties. This week we announced that we signed an agreement with a Midwestern distributor. We are targeting distributors with highly specialized sales forces that have the ability to both educate and inform anesthesiologists on the clinical benefits of the CompuFlo® Epidural System. In addition, we are in discussions with distributors around the world and look forward to having the results of our clinical trials published in leading industry journals later this year, which should help drive market adoption. At the end of March, we announced that Health Canada issued a medical device license for the CompuFlo® Epidural System. This is another important step and validation in our global roll-out strategy.”
“As anticipated, we experienced a short term weakness within our dental division in the first quarter of 2018. This was due to the timing of domestic and international promotions, as well as the timing and revenue recognition of orders from China. Nevertheless, we anticipate our dental division will achieve continued growth and maintain solid margins in 2018. Last week, we announced that The Brookdale University Hospital and Medical Center in New York will now utilize The Wand® computer assisted anesthesia system for its advanced education program in Pediatric Dentistry. In addition, The Wand® will be incorporated for regular use in the Department of Dental Medicine & Oral Maxillofacial Surgery. We are pleased to see another university utilizing our technology in their curriculum and ongoing practice.”
For the three months ended March 31, 2018 and 2017, revenues were approximately $1.8 million and $3.7 million, respectively. The decrease in revenue was primarily due to the revenue recognition of orders from China and advanced purchases from Henry Schein in the fourth quarter of 2017 due to the planned price increase in 2018. The gross profit for the first quarter ended March 31, 2018 was $1.2 million, or 69% of revenue, versus $2.3 million, or 62% of revenue for the first quarter ended March 31, 2017. Net loss for the three months ended March 31, 2018 was $(1.9) million, or $(0.06) per share, versus a net loss of $(0.57) million, or $(0.02) per share, in the prior year.
Conference Call
Milestone Scientific’s executive management team will host a conference call at 8:00 AM Eastern Time on Wednesday, May 16, 2018 to discuss the Company’s financial results for the first quarter ended March 31, 2018, as well as the Company’s corporate progress and other developments.
The conference call will be available on the Company’s website at www.milestonescientific.com, or via telephone by dialing toll free 800-263-0877 and entering the pass code: 6112920. For those unable to participate at that time, a replay of the call will be archived on the company’s website or can be accessed by dialing 888-203-1112 and entering the pass code 6112920. The replay will be available for 90 days.
About Milestone Scientific Inc.
Milestone Scientific Inc. (MLSS) is a biomedical technology research and development company that patents, designs and develops innovative diagnostic and therapeutic injection technologies and instruments for medical, dental, cosmetic and veterinary applications. Milestone's computer-controlled systems are designed to make injections precise, efficient, and virtually painless. Milestone’s proprietary DPS Dynamic Pressure Sensing technology® is our technology platform that advances the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions for local anesthesia for subcutaneous drug delivery, with specific applications for cosmetic botulinum toxin injections, epidural space identification in regional anesthesia procedures and intra-articular joint injections. For more information please visit our website: www.milestonescientific.com.
Safe Harbor Statement
This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues, timing of regulatory approvals and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions, future business decisions and regulatory developments, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2016. The forward looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.
| MILESTONE SCIENTIFIC INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEET |
||||||||
| March 31, 2018 |
December 31, 2017 |
|||||||
| ASSETS | (Unaudited) | (Audited) | ||||||
| Current Assets: | ||||||||
| Cash and cash equivalents | $ | 2,094,238 | $ | 2,636,956 | ||||
| Accounts receivable, net | 833,836 | 1,535,513 | ||||||
| Accounts receivable from related party | 1,725,450 | 1,725,450 | ||||||
| Notes receivable from financing transaction, current | 500,000 | 500,000 | ||||||
| Prepaid expenses and other current assets | 494,717 | 436,410 | ||||||
| Deferred cost related party | 1,109,671 | 1,109,671 | ||||||
| Inventories, net | 3,265,058 | 3,379,209 | ||||||
| Advances on contracts | 984,408 | 697,192 | ||||||
| Total current assets | 11,007,378 | 12,020,401 | ||||||
| Furniture, fixtures & equipment, net | 115,502 | 141,760 | ||||||
| Patents, net | 2,552,382 | 2,789,748 | ||||||
| Notes receivable from financing transaction, noncurrent | 650,000 | 650,000 | ||||||
| Other assets | 26,878 | 26,878 | ||||||
| Total assets | $ | 14,352,140 | $ | 15,628,787 | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| Current Liabilities: | ||||||||
| Accounts payable | $ | 1,556,689 | $ | 977,623 | ||||
| Accounts payable related party | 1,075,078 | 985,678 | ||||||
| Accrued expenses and other payables | 1,928,654 | 2,287,908 | ||||||
| Deferred profit, related party | 714,717 | 751,500 | ||||||
| Deferred revenue, related party | 1,725,450 | 1,725,450 | ||||||
| Total current liabilities | 7,000,588 | 6,728,159 | ||||||
| Deferred gain from financing transaction | 1,400,000 | 1,400,000 | ||||||
| Total liabilities | 8,400,588 | 8,128,159 | ||||||
| Commitments and Contingencies | ||||||||
|
Stockholders’ Equity |
||||||||
| Series A convertible preferred stock, par value $.001, authorized 5,000,000 shares, and 7,000 shares issued and outstanding as of March 31, 2018 and December 31, 2017 |
7 | 7 | ||||||
| Common stock, par value $.001; authorized 50,000,000 shares; 33,216,571 shares issued, 1,699,323 shares to be issued and 33,183,238 shares outstanding as of March 31, 2018; 33,191,571 shares issued, 1,401,247 shares to be issued and 33,158,238 shares outstanding as of December 31, 2017; |
34,916 | 34,593 | ||||||
| Additional paid-in capital | 87,115,070 | 86,689,084 | ||||||
| Accumulated deficit | (80,442,262 | ) | (78,568,284 | ) | ||||
| Treasury stock, at cost, 33,333 shares | (911,516 | ) | (911,516 | ) | ||||
| Total Milestone Scientific Inc. stockholders' equity | 5,796,215 | 7,243,884 | ||||||
| Noncontrolling interest | 155,337 | 256,744 | ||||||
| Total stockholders’ equity | 5,951,552 | 7,500,628 | ||||||
| Total liabilities and stockholders’ equity | $ | 14,352,140 | $ | 15,628,787 | ||||
| MILESTONE SCIENTIFIC INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) |
||||||||
| For the Three Months Ended | ||||||||
| March 31, 2018 |
March 31, 2017 |
|||||||
| Revenue | ||||||||
| Product sales, net | $ | 1,805,605 | $ | 3,688,988 | ||||
| Cost of products sold | 562,676 | 1,402,285 | ||||||
| Gross profit | 1,242,929 | 2,286,703 | ||||||
| Selling, general and administrative expenses | 3,018,780 | 2,707,620 | ||||||
| Research and development expenses | 225,817 | 105,015 | ||||||
| Total operating expenses | 3,244,597 | 2,812,635 | ||||||
| Loss from operations | (2,001,668 | ) | (525,932 | ) | ||||
| Other expenses | (1,700 | ) | (1,209 | ) | ||||
| Interest income | 2,664 | 758 | ||||||
| Loss before provision for income taxes and equity in net losses of equity investments | (2,000,704 | ) | (526,383 | ) | ||||
| Provision for income taxes | (11,464 | ) | (7,201 | ) | ||||
| Loss before equity in net losses of equity investments | (2,012,168 | ) | (533,584 | ) | ||||
| Loss on earnings from China Joint Venture | 36,783 | (44,401 | ) | |||||
| Net loss | (1,975,385 | ) | (577,985 | ) | ||||
| Net loss attributable to noncontrolling interests | (101,407 | ) | (73,117 | ) | ||||
| Net loss attributable to Milestone Scientific Inc. | $ | (1,873,978 | ) | $ | (504,868 | ) | ||
| Net loss per share applicable to common stockholders— | ||||||||
| Basic | $ | (0.06 | ) | $ | (0.02 | ) | ||
| Diluted | $ | (0.06 | ) | $ | (0.02 | ) | ||
| Weighted average shares outstanding and to be issued— | ||||||||
| Basic | 34,766,014 | 32,004,548 | ||||||
| Diluted | 34,766,014 | 32,004,548 | ||||||
| MILESTONE SCIENTIFIC INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) |
||||||||
| March 31, 2018 |
March 31, 2017 |
|||||||
| Cash flows from operating activities: | ||||||||
| Net loss | $ | (1,975,385 | ) | $ | (577,985 | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Depreciation expense | 27,625 | 16,860 | ||||||
| Amortization of patents | 237,366 | 17,682 | ||||||
| Stock compensation | 86,809 | 116,718 | ||||||
| Equity income on China joint venture | (36,783 | ) | - | |||||
| Changes in operating assets and liabilities: | ||||||||
| Decrease (increase) in accounts receivable | 701,677 | (824,182 | ) | |||||
| Decrease in accounts receivable related party | - | 1,400,801 | ||||||
| Decrease in inventories | 114,151 | 68,885 | ||||||
| Increase to in advances on contracts | (287,216 | ) | (161,114 | ) | ||||
| Increase in prepaid expenses and other current assets | (58,307 | ) | (207,613 | ) | ||||
| Increase in other assets | - | (9,523 | ) | |||||
| Decrease in deferred cost, related party | - | 438,925 | ||||||
| Increase (decrease) in accounts payable | 579,070 | (452,157 | ) | |||||
| Increase (decrease) in accounts payable related party | 89,400 | (152,748 | ) | |||||
| (Decrease) increase in accrued expenses and other payables | (19,757 | ) | 96,841 | |||||
| (Decrease) in deferred revenue, related party | - | (645,400 | ) | |||||
| Net cash used in operating activities | (541,350 | ) | (874,010 | ) | ||||
| Cash flows from investing activities: | ||||||||
| Purchase of property and equipment | (1,368 | ) | - | |||||
| Net cash used in investing activities | (1,368 | ) | - | |||||
| Cash flows from financing activities: | ||||||||
| Net proceeds on Public offering | - | 150,836 | ||||||
| Proceeds from exercise of stock options | - | 62,500 | ||||||
| Net cash provided by financing activities | - | 213,336 | ||||||
| Net decrease in cash and cash equivalents | (542,718 | ) | (660,674 | ) | ||||
| Cash and cash equivalents at beginning of period | 2,636,956 | 3,602,229 | ||||||
| Cash and cash equivalents at end of period | $ | 2,094,238 | $ | 2,941,555 | ||||
| Supplemental disclosure of cash flow information: | ||||||||
| Shares issued to employees for bonuses | $ | 359,254 | $ | 195,000 | ||||
| Shares issued to consultants in lieu of cash payments | $ | - | $ | 43,750 | ||||
Contact:
David Waldman or Natalya Rudman
Crescendo Communications, LLC
Email: mlss@crescendo-ir.com
Tel: 212-671-1020